產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-LGI4抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-LGI4抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-LGI4
Cat. Number:
Anti-LGI4抗體KL-8303R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LGI4, also known as leucine-rich glioma-inactivated protein 4, is a 537 amino acid secreted glycosylated protein that is widely expressed, with highest levels found within the nervous system. Interestingly, siRNA knockdown studies of LGI4 expression in Schwann cells have been shown to result in the inhibition of myelination, thus suggesting that LGI4 is an essential component of myelin formation and axon segregation. Anti-LGI4抗體LGI4 shares significant homology with its other family members, LGI1, LGI2 and LGI3. Significantly, mutations in the gene encoding LGI1 have been linked to human temporal lobe epilepsy and, given the sequence similarity of LGI4, it is likely that it also may be implicated in the pathology of seizures. LGI4 is localized subcellularly to the Golgi, ER and vesicles. There are two isoforms of LGI4 that are produced as a result of alternative splicing events.
Also known as:
Leucine rich glioma inactivated gene 4; Leucine rich glioma inactivated protein 4; leucine-rich repeat LGI family member 4; Leucine Anti-LGI4抗體rich repeat LGI family member 4; LGI1 like protein 3; LGI4; Lgi4 protein; Lgil3; LGI4_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugatedAnti-LGI4抗體 synthetic peptide derived from human LGI4.
●
Predicted Molecular Weight: 57kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-LGI4抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-LGI4抗體
Optimal working dilutions must be determined by the end user.
